NuGen Medical Devices Inc.
NGMDF
$0.068
$0.022549.45%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 307.87% | 373.94% | 214.89% | 106.49% | 9.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 307.87% | 373.94% | 214.89% | 106.49% | 9.40% |
| Cost of Revenue | 422.18% | 400.38% | 172.39% | 100.16% | 0.53% |
| Gross Profit | 226.96% | 350.71% | 274.71% | 113.09% | 16.67% |
| SG&A Expenses | -5.84% | 8.69% | 52.80% | 56.18% | 11.29% |
| Depreciation & Amortization | -18.12% | -8.87% | -1.38% | 34.98% | -18.07% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.69% | 8.86% | 47.48% | 54.85% | 7.14% |
| Operating Income | 10.67% | -4.53% | -44.03% | -53.28% | -7.08% |
| Income Before Tax | 3.79% | -1.60% | -37.78% | -54.15% | -4.72% |
| Income Tax Expenses | 274.65% | 190.91% | 2,666.67% | 857.69% | 407.14% |
| Earnings from Continuing Operations | 3.48% | -1.82% | -38.26% | -54.61% | -4.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.48% | -1.82% | -38.26% | -54.61% | -4.81% |
| EBIT | 10.67% | -4.53% | -44.03% | -53.28% | -7.08% |
| EBITDA | 11.16% | -5.26% | -47.14% | -58.05% | -7.73% |
| EPS Basic | 38.70% | 41.72% | 28.46% | 17.35% | 32.58% |
| Normalized Basic EPS | 37.13% | 39.37% | 30.58% | 21.07% | 36.83% |
| EPS Diluted | 38.70% | 41.72% | 28.46% | 17.35% | 32.58% |
| Normalized Diluted EPS | 37.13% | 39.37% | 30.58% | 21.07% | 36.83% |
| Average Basic Shares Outstanding | 50.32% | 74.47% | 95.70% | 91.62% | 61.14% |
| Average Diluted Shares Outstanding | 50.32% | 74.47% | 95.70% | 91.62% | 61.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |